Plain-English translation of NCT07419347 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is looking at the safety and effectiveness of glecaprevir/pibrentasvir, a medication used to treat hepatitis C, in people who are also taking other medicines or drugs. Researchers will collect real-world data from about 2,000 patients who receive this 8-week treatment course to understand how well the medication works and whether it causes any problems when combined with other substances.
Most people with hepatitis C also take other medications or may use other drugs, but many clinical trials test treatments in patients who are taking nothing else. This study exists to fill that gap by examining how this medication actually performs in real-world patients with complex medical situations.
You likely qualify if…
You likely don't qualify if…
This is a data collection study, not a traditional clinical trial where you receive new treatment. Researchers will gather information from your medical records about your hepatitis C treatment with this medication and any other drugs you take during those 8 weeks. You may be asked to share details about your health history and how you respond to the treatment, but the study uses existing medical data rather than requiring frequent clinic visits or new procedures.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Canada
Sponsor
AbbVie
Enrollment target
~2,000 participants
Started
February 2026
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dimitri Semizarov
AbbVie
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.